Go to content
UR Home

Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature

URN to cite this document:
DOI to cite this document:
Dohrn, Maike F. ; Auer-Grumbach, Michaela ; Baron, Ralf ; Birklein, Frank ; Escolano-Lozano, Fabiola ; Geber, Christian ; Grether, Nicolai ; Hagenacker, Tim ; Hund, Ernst ; Sachau, Juliane ; Schilling, Matthias ; Schmidt, Jens ; Schulte-Mattler, Wilhelm ; Sommer, Claudia ; Weiler, Markus ; Wunderlich, Gilbert ; Hahn, Katrin
[img]License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 11 Oct 2021 13:08


Hereditary transthyretin amyloidosis is caused by pathogenic variants (ATTR(v)) in the TTR gene. Alongside cardiac dysfunction, the disease typically manifests with a severely progressive sensorimotor and autonomic polyneuropathy. Three different drugs, tafamidis, patisiran, and inotersen, are approved in several countries, including the European Union and the United States of America. By ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons